Format

Send to

Choose Destination
Mol Cell Endocrinol. 2014 Jan 25;382(1):665-672. doi: 10.1016/j.mce.2013.08.005. Epub 2013 Aug 15.

Estrogen receptor beta in breast cancer.

Author information

1
Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83 Huddinge, Sweden. Electronic address: lars-arne.haldosen@ki.se.
2
Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83 Huddinge, Sweden. Electronic address: chunyan.zhao@ki.se.
3
Department of Biosciences and Nutrition, Karolinska Institutet, SE-141 83 Huddinge, Sweden. Electronic address: karin.dahlman-wright@ki.se.

Abstract

Estrogen is essential for growth and development of the mammary glands and has been associated with the promotion and growth of breast cancer and in line with this, most human breast cancers are initially estrogen-dependent and undergo regression when deprived of their supporting hormone. Estrogen exerts many of its effects via two nuclear estrogen receptors (ERs), ERα and ERβ. The discovery of a second ER, ERβ, demanded a full re-evaluation of estrogen action in all target tissues and different estrogen associated diseases, including human breast cancer. However, despite over 15 years of research, the exact role, if any, of ERβ in human breast cancer remains elusive. The main challenges now are to develop highly selective anti-ERβ antibodies that are applied to large well characterized human breast cancer samples to validate their diagnostic potential and to explore ERβ-selective agonists in animal models of breast cancer to validate their therapeutic potential.

KEYWORDS:

Breast cancer; Breast cancer marker; ERbeta isoforms; Estrogen receptor beta

PMID:
23954741
DOI:
10.1016/j.mce.2013.08.005
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center